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Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment for major 19 depressive disorder [1] . Recently, we investigated 10 sessions of high-frequency rTMS applied 20 to the left dorsolateral prefrontal cortex (DLPFC) in chronic stroke survivors with depression 21 (randomised controlled trial; ACTRN12619001303134; institutional ethics approval 200697). 22 Stimulation was delivered at 110% resting motor threshold at 10 Hz for a total of 3000 pulses. 23 Here we report the experience of a 51-year-old male with mild upper-limb impairment Meyer 49/66; structural imaging Figure 1 ), who experienced anatomically confined stimulus-25 evoked dental pain in response to sham stimulation. 26 27 Prior to inclusion, the participant was screened for brain stimulation safety [2] . There were no 28 contraindications and no noteworthy medical history beyond a stroke three years prior. Current 29 medications were anti-depressants and anti-coagulants with dosage stable for more than 6-30 months. The participant had previously participated in transcranial direct current stimulation 31 research more than two months prior with no adverse events beyond standard transient 32 symptoms documented in the literature [3] . Therefore, the participant was deemed safe for 33 rTMS, included in the trial and was progressed to full initial assessment.
35
After initial assessment, the participant was informed that there was an active and sham 36 condition in this trial and that he would be blinded to allocation. He was randomised to receive 37 sham rTMS. The session began at 10:30am. Threshold of the left motor cortex was 52% 38 maximal stimulator (Magstim Super Rapid) output using a Magstim 70mm figure 8 air film coil 39 (part-number 3910-23-00). Sham rTMS was delivered with a Magstim 70 mm figure 8 air film 40 placebo coil (part-number 3950-23-00) to the left DLPFC at 57% maximal stimulator output. 41 Immediately upon delivery of sham rTMS, he recoiled his head away from the stimulation coil 42 and reported strong pain on the left side of his face. Stimulation was immediately stopped. Pain 43 resolved almost instantly. On further questioning, the participant described the discomfort as a 44 strong stabbing pain in his upper and lower teeth, posterior to his left incisors, and extending 45 into and along his mandible. Several attempts were made to optimise coil position or adjust 46 stimulation intensity (down to 50%). However, the same pain occurred with each stimulation and resolved immediately. That is, the pain appeared to be directly evoked by sham rTMS over 48 the left DLPFC. No other sensory or motor symptoms were reported; no motor signs were 49 observed. On further questioning, the participant recalled that two weeks earlier he had 50 undergone a dental procedure that included a filling to a left upper molar. He had not raised 51 this earlier because it did not appear relevant and it had not been associated with symptoms 52 then or since. 
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